← Back to Screener
MacroGenics, Inc. (MGNX)
Price$3.48
Favorite Metrics
Price vs S&P 500 (26W)95.99%
Price vs S&P 500 (4W)11.49%
Market Capitalization$228.17M
All Metrics
Book Value / Share (Quarterly)$0.88
P/TBV (Annual)3.28x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-0.53%
Cash Flow / Share (Quarterly)$-1.31
Price vs S&P 500 (YTD)110.77%
Gross Margin (TTM)75.91%
Net Profit Margin (TTM)-49.91%
EPS (TTM)$-1.18
10-Day Avg Trading Volume0.97M
EPS Excl Extra (TTM)$-1.18
Revenue Growth (5Y)7.34%
EPS (Annual)$-1.18
ROI (Annual)-59.42%
Gross Margin (Annual)75.91%
Net Profit Margin (5Y Avg)-89.99%
Cash / Share (Quarterly)$3.00
Revenue Growth QoQ (YoY)113.03%
ROA (Last FY)-29.05%
Revenue Growth TTM (YoY)-0.31%
EBITD / Share (TTM)$-0.94
ROE (5Y Avg)-73.32%
Operating Margin (TTM)-48.72%
Cash Flow / Share (Annual)$-1.31
P/B Ratio4.10x
P/B Ratio (Quarterly)1.83x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)1.61x
Net Interest Coverage (TTM)-13.74x
ROA (TTM)-29.92%
EPS Growth QoQ (YoY)-70.10%
EV / EBITDA (TTM)110.89x
EPS Incl Extra (Annual)$-1.18
Current Ratio (Annual)5.10x
Quick Ratio (Quarterly)4.71x
3-Month Avg Trading Volume1.26M
52-Week Price Return193.22%
Revenue / Employee (TTM)$1
Tangible BV / Share (Quarterly)$3.13
P/S Ratio (Annual)1.53x
Asset Turnover (Annual)0.58x
52-Week High$3.88
Operating Margin (5Y Avg)-93.94%
EPS Excl Extra (Annual)$-1.18
CapEx CAGR (5Y)-20.19%
Tangible BV CAGR (5Y)-13.85%
26-Week Price Return104.73%
Quick Ratio (Annual)4.71x
13-Week Price Return94.38%
Total Debt / Equity (Annual)1.26x
Current Ratio (Quarterly)5.10x
Enterprise Value$240.955
Revenue / Share Growth (5Y)3.41%
Asset Turnover (TTM)0.60x
Book Value / Share Growth (5Y)-30.10%
Revenue / Employee (Annual)$1
Inventory Turnover (Annual)9.10x
Pretax Margin (Annual)-50.36%
Cash / Share (Annual)$3.00
3-Month Return Std Dev110.94%
Gross Margin (5Y Avg)89.11%
Net Income / Employee (TTM)$-0
ROE (Last FY)-134.23%
Net Interest Coverage (Annual)-7.85x
EPS Basic Excl Extra (Annual)$-1.18
P/FCF (TTM)5.33x
Receivables Turnover (TTM)16.91x
EV / Free Cash Flow (TTM)3.52x
Total Debt / Equity (Quarterly)1.26x
EPS Incl Extra (TTM)$-1.18
Receivables Turnover (Annual)16.91x
ROI (TTM)-65.05%
P/S Ratio (TTM)1.53x
Pretax Margin (5Y Avg)-89.96%
Revenue / Share (Annual)$2.37
Tangible BV / Share (Annual)$2.30
Price vs S&P 500 (52W)158.13%
Year-to-Date Return114.91%
5-Day Price Return-0.29%
EPS Normalized (Annual)$-1.18
ROA (5Y Avg)-32.14%
Net Profit Margin (Annual)-49.91%
Month-to-Date Return19.72%
Cash Flow / Share (TTM)$0.98
EBITD / Share (Annual)$-1.00
Operating Margin (Annual)-48.72%
LT Debt / Equity (Annual)1.26x
ROI (5Y Avg)-58.36%
LT Debt / Equity (Quarterly)1.26x
EPS Basic Excl Extra (TTM)$-1.18
P/TBV (Quarterly)2.40x
P/B Ratio (Annual)1.83x
Inventory Turnover (TTM)9.10x
Pretax Margin (TTM)-50.36%
Book Value / Share (Annual)$0.88
Price vs S&P 500 (13W)91.52%
Beta1.17x
P/FCF (Annual)36.45x
Revenue / Share (TTM)$2.36
ROE (TTM)-120.20%
52-Week Low$1.10
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
3.77
3.77
3.77
3.77
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
MGNXMacroGenics, Inc. | 1.53x | -0.31% | 75.91% | — | $3.48 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Macrogenics Inc. is a biotechnology company developing antibody-based therapeutics for cancer treatment. The company's marketed product, MARGENZA, is approved for metastatic HER2-positive breast cancer. Its pipeline includes three clinical-stage candidates: lorigerlimab, a bispecific DART targeting immune checkpoints PD-1 and CTLA-4; MGC026, targeting B7-H3; and MGC028, targeting ADAM9, each utilizing novel topoisomerase I inhibitor-based linker-payloads.